J. S. Blackburn

This study identifies Erlotinib as a Wnt/β-catenin inhibitor effective in zebrafish and human cells, reducing leukemia-initiating cell self-renewal and disease progression.

This paper develops and validates nanobodies that specifically target PRL-3, showing high specificity over PRL-1 and PRL-2 and providing tools to study PRL-3 function in cancer.

The paper screens FDA-approved drugs to identify inhibitors of PTP4A3 (PRL-3), finding five specific inhibitors and two broad inhibitors that block PRL-3-induced migration without affecting cell viability.

The paper uses in vivo imaging in zebrafish to study how vascular networks support leukemia cell dissemination and finds that leukemic cells use VEGFR2-microvessels during early progression.